2nd 0 3 0 3 B-chronic_disease
- 3 4 3 4 I-chronic_disease
degree 4 10 4 10 I-chronic_disease
atrioventricular 11 27 11 27 I-chronic_disease
( 28 29 28 29 I-chronic_disease
AV 29 31 29 31 I-chronic_disease
) 31 32 31 32 I-chronic_disease
block 33 38 33 38 I-chronic_disease
type 39 43 39 43 I-chronic_disease
II 44 46 44 46 I-chronic_disease

For 0 3 47 50 O
subjects 4 12 51 59 O
with 13 17 60 64 O
ALL 18 21 65 68 B-cancer
or 22 24 69 71 O
AML 25 28 72 75 B-cancer
, 28 29 75 76 O
presence 30 38 77 85 O
of 39 41 86 88 O
> 42 43 89 90 O
5 43 44 90 91 B-lower_bound
% 44 45 91 92 I-lower_bound
blasts 46 52 93 99 O
in 53 55 100 102 O
the 56 59 103 106 O
bone 60 64 107 111 O
marrow 65 71 112 118 O
( 72 73 119 120 O
based 73 78 120 125 O
on 79 81 126 128 O
a 82 83 129 130 O
bone 84 88 131 135 B-treatment
marrow 89 95 136 142 I-treatment
aspirate 96 104 143 151 I-treatment
/ 104 105 151 152 I-treatment
biopsy 105 111 152 158 I-treatment
sample 112 118 159 165 O
with 119 123 166 170 O
≥200 124 128 171 175 O
nucleated 129 138 176 185 B-clinical_variable
cells 139 144 186 191 I-clinical_variable
and 145 148 192 195 O
the 149 152 196 199 O
presence 153 161 200 208 O
of 162 164 209 211 O
bone 165 169 212 216 O
marrow 170 176 217 223 O
spicules 177 185 224 232 O
) 185 186 232 233 O

For 0 3 234 237 O
subjects 4 12 238 246 O
with 13 17 247 251 O
DLBCL 18 23 252 257 B-cancer
, 23 24 257 258 O
FL 25 27 259 261 B-cancer
, 27 28 261 262 O
MCL 29 32 263 266 B-cancer
, 32 33 266 267 O
HL 34 36 268 270 B-cancer
, 36 37 270 271 O
or 38 40 272 274 O
CLL 41 44 275 278 B-cancer
/ 44 45 278 279 O
SLL 45 48 279 282 B-cancer
: 48 49 282 283 O
presence 50 58 284 292 O
of 59 61 293 295 O
radiographically 62 78 296 312 O
measurable 79 89 313 323 O
lymphadenopathy 90 105 324 339 O
or 106 108 340 342 O
extranodal 109 119 343 353 O
lymphoid 120 128 354 362 O
malignancy 129 139 363 373 O
( 140 141 374 375 O
defined 141 148 375 382 O
as 149 151 383 385 O
the 152 155 386 389 O
presence 156 164 390 398 O
of 165 167 399 401 O
≥1 168 170 402 404 O
lesion 171 177 405 411 O
that 178 182 412 416 O
measures 183 191 417 425 O
≥2.0 192 196 426 430 O
cm 197 199 431 433 I-lower_bound
in 200 202 434 436 O
the 203 206 437 440 O
longest 207 214 441 448 O
dimension 215 224 449 458 O
[ 225 226 459 460 O
LD 226 228 460 462 O
] 228 229 462 463 O
and 230 233 464 467 O
≥1.0 234 238 468 472 O
cm 239 241 473 475 I-lower_bound
in 242 244 476 478 O
the 245 248 479 482 O
longest 249 256 483 490 O
perpendicular 257 270 491 504 O
dimension 271 280 505 514 O
[ 281 282 515 516 O
LPD 282 285 516 519 O
] 285 286 519 520 O
as 287 289 521 523 O
assessed 290 298 524 532 O
by 299 301 533 535 O
computed 302 310 536 544 O
tomography 311 321 545 555 O
[ 322 323 556 557 O
CT 323 325 557 559 O
] 325 326 559 560 O
) 326 327 560 561 O

For 0 3 562 565 O
subjects 4 12 566 574 O
with 13 17 575 579 O
MM 18 20 580 582 B-chronic_disease
, 20 21 582 583 O
measurable 22 32 584 594 O
disease 33 40 595 602 O
with 41 45 603 607 O
serum 46 51 608 613 B-clinical_variable
monoclonal 52 62 614 624 I-clinical_variable
immunoglobulin 63 77 625 639 I-clinical_variable
protein 78 85 640 647 I-clinical_variable
( 86 87 648 649 I-clinical_variable
M 87 88 649 650 I-clinical_variable
- 88 89 650 651 I-clinical_variable
protein 89 96 651 658 I-clinical_variable
) 96 97 658 659 I-clinical_variable
≥1 98 100 660 662 O
g 101 102 663 664 I-lower_bound
/ 102 103 664 665 I-lower_bound
dL 103 105 665 667 I-lower_bound
, 105 106 667 668 O
or 107 109 669 671 O
urine 110 115 672 677 B-clinical_variable
M 116 117 678 679 I-clinical_variable
- 117 118 679 680 I-clinical_variable
protein 118 125 680 687 I-clinical_variable
protein 126 133 688 695 I-clinical_variable
≥200 134 138 696 700 O
mg/24 139 144 701 706 I-lower_bound
hours 145 150 707 712 O
, 150 151 712 713 O
or 152 154 714 716 O
involved 155 163 717 725 O
serum 164 169 726 731 B-clinical_variable
free 170 174 732 736 I-clinical_variable
light 175 180 737 742 I-clinical_variable
chain 181 186 743 748 I-clinical_variable
( 187 188 749 750 I-clinical_variable
SFLC 188 192 750 754 I-clinical_variable
) 192 193 754 755 I-clinical_variable
≥10 194 197 756 759 O
mg 198 200 760 762 I-lower_bound
/ 200 201 762 763 I-lower_bound
dL 201 203 763 765 I-lower_bound

Grade 0 5 766 771 O
≥2 6 8 772 774 O
bradycardia 9 20 775 786 B-chronic_disease

Hematological 0 13 787 800 B-cancer
malignancy 14 24 801 811 I-cancer
has 25 28 812 815 O
been 29 33 816 820 O
previously 34 44 821 831 O
treated 45 52 832 839 O
, 52 53 839 840 O
has 54 57 841 844 O
relapsed 58 66 845 853 O
after 67 72 854 859 O
or 73 75 860 862 O
progressed 76 86 863 873 O
during 87 93 874 880 O
prior 94 99 881 886 B-treatment
therapy 100 107 887 894 I-treatment
, 107 108 894 895 O
and 109 112 896 899 O
has 113 116 900 903 O
limited 117 124 904 911 O
potential 125 134 912 921 O
for 135 138 922 925 O
benefit 139 146 926 933 O
from 147 151 934 938 O
currently 152 161 939 948 O
available 162 171 949 958 O
therapy 172 179 959 966 O

New 0 3 967 970 B-clinical_variable
York 4 8 971 975 I-clinical_variable
Heart 9 14 976 981 I-clinical_variable
Association 15 26 982 993 I-clinical_variable
Class 27 32 994 999 I-clinical_variable
3 33 34 1000 1001 B-lower_bound
or 35 37 1002 1004 O
4 38 39 1005 1006 B-upper_bound
congestive 40 50 1007 1017 B-chronic_disease
heart 51 56 1018 1023 I-chronic_disease
failure 57 64 1024 1031 I-chronic_disease

Ongoing 0 7 1032 1039 O
risk 8 12 1040 1044 O
for 13 16 1045 1048 O
bleeding 17 25 1049 1057 O
due 26 29 1058 1061 O
to 30 32 1062 1064 O
active 33 39 1065 1071 B-chronic_disease
peptic 40 46 1072 1078 I-chronic_disease
ulcer 47 52 1079 1084 I-chronic_disease
disease 53 60 1085 1092 I-chronic_disease

Part 0 4 1093 1097 O
1 5 6 1098 1099 O
( 7 8 1100 1101 O
Dose 8 12 1101 1105 O
Escalation 13 23 1106 1116 O
): 23 25 1116 1118 O
Diagnosis 26 35 1119 1128 O
of 36 38 1129 1131 O
B 39 40 1132 1133 B-chronic_disease
- 40 41 1133 1134 I-chronic_disease
cell 41 45 1134 1138 I-chronic_disease
DLBCL 46 51 1139 1144 I-chronic_disease
, 51 52 1144 1145 O
FL 53 55 1146 1148 B-chronic_disease
, 55 56 1148 1149 O
MCL 57 60 1150 1153 B-chronic_disease
, 60 61 1153 1154 O
HL 62 64 1155 1157 B-chronic_disease
, 64 65 1157 1158 O
CLL 66 69 1159 1162 B-chronic_disease
/ 69 70 1162 1163 I-chronic_disease
SLL 70 73 1163 1166 I-chronic_disease
or 74 76 1167 1169 O
MM 77 79 1170 1172 B-chronic_disease
as 80 82 1173 1175 O
documented 83 93 1176 1186 O
by 94 96 1187 1189 O
medical 97 104 1190 1197 O
records 105 112 1198 1205 O

Part 0 4 1206 1210 O
2 5 6 1211 1212 O
( 7 8 1213 1214 O
Cohort 8 14 1214 1220 O
Expansion 15 24 1221 1230 O
): 24 26 1230 1232 O
Diagnosis 27 36 1233 1242 O
of 37 39 1243 1245 O
DLBCL 40 45 1246 1251 B-cancer
, 45 46 1251 1252 O
FL 47 49 1253 1255 B-cancer
, 49 50 1255 1256 O
MCL 51 54 1257 1260 B-cancer
, 54 55 1260 1261 O
HL 56 58 1262 1264 B-cancer
, 58 59 1264 1265 O
CLL 60 63 1266 1269 B-cancer
/ 63 64 1269 1270 O
SLL 64 67 1270 1273 B-cancer
, 67 68 1273 1274 O
ALL 69 72 1275 1278 B-cancer
, 72 73 1278 1279 O
MM 74 76 1280 1282 B-cancer
, 76 77 1282 1283 O
or 78 80 1284 1286 O
AML 81 84 1287 1290 B-cancer
as 85 87 1291 1293 O
documented 88 98 1294 1304 O
in 99 101 1305 1307 O
medical 102 109 1308 1315 O
records 110 117 1316 1323 O

Rapidly 0 7 1324 1331 O
progressive 8 19 1332 1343 O
, 19 20 1343 1344 O
clinically 21 31 1345 1355 O
unstable 32 40 1356 1364 O
central 41 48 1365 1372 O
nervous 49 56 1373 1380 O
system 57 63 1381 1387 O
hematological 64 77 1388 1401 B-cancer
malignancy 78 88 1402 1412 I-cancer

Subjects 0 8 1413 1421 O
with 9 13 1422 1426 O
localized 14 23 1427 1436 O
fungal 24 30 1437 1443 B-chronic_disease
infections 31 41 1444 1454 I-chronic_disease
of 42 44 1455 1457 O
skin 45 49 1458 1462 O
or 50 52 1463 1465 O
nails 53 58 1466 1471 O

Use 0 3 1472 1475 O
of 4 6 1476 1478 O
heparin 7 14 1479 1486 B-treatment
or 15 17 1487 1489 O
thrombolytic 18 30 1490 1502 B-treatment
agents 31 37 1503 1509 I-treatment
for 38 41 1510 1513 O
local 42 47 1514 1519 O
maintenance 48 59 1520 1531 O
or 60 62 1532 1534 O
clearance 63 72 1535 1544 O
of 73 75 1545 1547 O
a 76 77 1548 1549 O
central 78 85 1550 1557 O
venous 86 92 1558 1564 O
catheter 93 101 1565 1573 O

angina 0 6 1574 1580 B-chronic_disease
requiring 7 16 1581 1590 O
therapy 17 24 1591 1598 B-treatment

apixaban 0 8 1599 1607 B-treatment

atrial 0 6 1608 1614 B-chronic_disease
fibrillation 7 19 1615 1627 I-chronic_disease
/ 19 20 1627 1628 O
flutter 20 27 1628 1635 B-chronic_disease

bleeding 0 8 1636 1644 B-chronic_disease
diathesis 9 18 1645 1654 I-chronic_disease

dabigatran 0 10 1655 1665 B-treatment
etexilate 11 20 1666 1675 I-treatment

dalteparin 0 10 1676 1686 B-treatment

enoxaparin 0 10 1687 1697 B-treatment

extranodal 0 10 1698 1708 B-chronic_disease
organ 11 16 1709 1714 I-chronic_disease
involvement 17 28 1715 1726 I-chronic_disease

fondaparinux 0 12 1727 1739 B-treatment

hematopoietic 0 13 1740 1753 B-treatment
stem 14 18 1754 1758 I-treatment
cell 19 23 1759 1763 I-treatment
transplantation 24 39 1764 1779 I-treatment

heparin 0 7 1780 1787 B-treatment
fractions 8 17 1788 1797 O

left 0 4 1798 1802 B-chronic_disease
bundle 5 11 1803 1809 I-chronic_disease
- 11 12 1809 1810 I-chronic_disease
branch 12 18 1810 1816 I-chronic_disease
block 19 24 1817 1822 I-chronic_disease

low 0 3 1823 1826 B-treatment
- 3 4 1826 1827 I-treatment
molecular 4 13 1827 1836 I-treatment
- 13 14 1836 1837 I-treatment
weight 14 20 1837 1843 I-treatment
heparin 21 28 1844 1851 I-treatment

lymphadenopathy 0 15 1852 1867 B-chronic_disease

oral 0 4 1868 1872 B-treatment
anticoagulants 5 19 1873 1887 I-treatment

organomegaly 0 12 1888 1900 B-chronic_disease

progressive 0 11 1901 1912 B-chronic_disease
disease 12 19 1913 1920 I-chronic_disease

symptomatic 0 11 1921 1932 O
dysrhythmias 12 24 1933 1945 B-chronic_disease

symptomatic 0 11 1946 1957 B-chronic_disease
peripheral 12 22 1958 1968 I-chronic_disease
vascular 23 31 1969 1977 I-chronic_disease
disease 32 39 1978 1985 I-chronic_disease

unstable 0 8 1986 1994 B-chronic_disease
dysrhythmias 9 21 1995 2007 I-chronic_disease
requiring 22 31 2008 2017 O
medical 32 39 2018 2025 B-treatment
therapy 40 47 2026 2033 I-treatment

warfarin 0 8 2034 2042 B-treatment

